Clinical Trial Detail

NCT ID NCT02940496
Title Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

hepatocellular carcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.